183 related articles for article (PubMed ID: 7888604)
1. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
2. Circadian time dependence of murine tolerance for carboplatin.
Boughattas NA; Lévi F; Hecquet B; Lemaigre G; Roulon A; Fournier C; Reinberg A
Toxicol Appl Pharmacol; 1988 Nov; 96(2):233-47. PubMed ID: 3057682
[TBL] [Abstract][Full Text] [Related]
3. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.
Boughattas NA; Lévi F; Fournier C; Hecquet B; Lemaigre G; Roulon A; Mathé G; Reinberg A
J Pharmacol Exp Ther; 1990 Nov; 255(2):672-9. PubMed ID: 2243347
[TBL] [Abstract][Full Text] [Related]
4. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice.
Boughattas NA; Lévi F; Fournier C; Lemaigre G; Roulon A; Hecquet B; Mathé G; Reinberg A
Cancer Res; 1989 Jun; 49(12):3362-8. PubMed ID: 2720689
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745
[TBL] [Abstract][Full Text] [Related]
6. Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in mice.
Li XM; Metzger G; Filipski E; Lemaigre G; Lévi F
Arch Toxicol; 1998 Sep; 72(9):574-9. PubMed ID: 9806429
[TBL] [Abstract][Full Text] [Related]
7. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
Mulder PO; de Vries EG; Uges DR; Scaf AH; Sleijfer DT; Mulder NH
Br J Cancer; 1990 Mar; 61(3):460-4. PubMed ID: 2183874
[TBL] [Abstract][Full Text] [Related]
9. The drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a day.
Yang K; Zhao N; Zhao D; Chen D; Li Y
Drug Des Devel Ther; 2013; 7():511-7. PubMed ID: 23818762
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits.
Kizu R; Higashi S; Kidani Y; Miyazaki M
Cancer Chemother Pharmacol; 1993; 31(6):475-80. PubMed ID: 8453687
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
12. Diurnal expression of MRP4 in bone marrow cells underlies the dosing-time dependent changes in the oxaliplatin-induced myelotoxicity.
Kato M; Tsurudome Y; Kanemitsu T; Yasukochi S; Kanado Y; Ogino T; Matsunaga N; Koyanagi S; Ohdo S
Sci Rep; 2020 Aug; 10(1):13484. PubMed ID: 32778717
[TBL] [Abstract][Full Text] [Related]
13. Biotransformations of oxaliplatin in rat blood in vitro.
Luo FR; Wyrick SD; Chaney SG
J Biochem Mol Toxicol; 1999; 13(3-4):159-69. PubMed ID: 10098901
[TBL] [Abstract][Full Text] [Related]
14. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion.
Lerza R; Vannozzi MO; Tolino G; Viale M; Bottino GB; Bogliolo G; Cerruti A; Castello G; Mencoboni M; Reggiardo G; Pannacciulli I; Esposito M
Ann Oncol; 1997 Apr; 8(4):385-91. PubMed ID: 9209670
[TBL] [Abstract][Full Text] [Related]
16. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer.
Cattel L; La Grotta G; Infante L; Passera R; Arpicco S; Brusa P; Bumma C
Farmaco; 2003 Dec; 58(12):1333-8. PubMed ID: 14630248
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
20. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
